IP Library Granted Patent US 11,951,137
Granted Patent B2
US 11,951,137 · App. 17/206,851 · Granted Apr 9, 2024

Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions

Inventor: Yuanlong Pan (Chesterfield, MO)
Assignee: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
A61K35/60A23D9/007A23K10/18A23K20/158A23K50/40A23L33/115A23L33/12A23L33/175A61K31/198A61K31/20A61K31/202A61K31/22A61K31/4375A61K31/445A61K31/454A61K31/522A61K31/54A61K31/55A61K31/56A61K31/663A61K31/675A61K31/683A61K36/16A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,951,137
App. No.
17/206,851
Granted
Apr 9, 2024
Kind
B2
Abstract

Compositions include arginine and one or more unsaturated fatty acids. Methods for using such compositions can enhance cognitive function, reduce or prevent a decline of social interaction, reduce or prevent age-related behavioral changes, increase trainability, maintain optimal brain function, facilitate learning and memory, reduce memory loss, retard brain aging, prevent or treat strokes, and/or prevent or treat dementia in an animal. Preferably, the compositions are food compositions useful for enhancing cognitive function in humans and companion animals.

Claims (24)

1. A method of enhancing cognitive function in an aging companion animal, the method comprising:

administering a composition to the aging companion animal on a daily basis, the aging companion animal is an aging canine or aging feline, the composition comprising effective amounts of arginine and docosahexaenoic acid (DHA), wherein the DHA is about 0.1% to about 50% of the composition, and the administering of the composition on a daily basis for a time period results in enhanced cognitive function in the aging companion animal compared with an equivalent aging companion animal not administered the composition for an equivalent time period.

2. The method of claim 1 , wherein the arginine is about 0.1% to about 20% of the composition.

3. The method of claim 1 , wherein the composition comprises one or more of a natural fish oil, alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), or another n−3 fatty acid from any source.

4. The method of claim 1 wherein the time period is at least one month.

5. The method of claim 1 , wherein the composition is a complete and nutritionally balanced pet food.

6. The method of claim 1 , wherein the composition is administered in a daily dose comprising about 0.001 g of the DHA/kg body weight of the aging companion animal to about 50 g of the DHA/kg body weight of the aging companion animal per day.

7. The method of claim 1 , wherein the composition is administered in a daily dose comprising about 0.001 g of the DHA/kg body weight of the aging companion animal to about 0.5 g of the DHA/kg body weight of the aging companion animal per day.

8. The method of claim 1 , wherein the composition is administered in a daily dose comprising about 0.001 g of the arginine/kg body weight of the aging companion animal to about 50 g of the arginine/kg body weight of the aging companion animal per day.

9. The method of claim 1 , wherein the composition is administered in a daily dose comprising about 0.001 g of the arginine/kg body weight of the aging companion animal to about 0.5 g of the arginine/kg body weight of the aging companion animal per day.

10. The method of claim 1 , wherein the aging companion animal is a healthy aging companion animal, and the administration of the DHA and the arginine results in enhanced cognitive function in the healthy aging companion animal relative to an equivalent healthy aging companion animal not administered the DHA and the arginine.

11. The method of claim 1 , wherein the aging companion animal has a phenotype associated with age-related cognitive impairment, and the administration of the DHA and the arginine results in enhanced cognitive function in the aging companion animal relative to an equivalent aging companion animal having the phenotype associated with age-related cognitive impairment and not administered the DHA and the arginine.

12. The method of claim 11 , wherein the phenotype comprises one or more of decreased ability to recall, short-term memory loss, decreased learning rate, decreased capacity for learning, decreased problem solving skills, decreased attention span, decreased motor performance, increased confusion, or dementia, as compared to a control aging companion animal not having the phenotype.

13. The method of claim 11 , wherein the phenotype comprises dementia.

14. The method of claim 1 , wherein the aging companion animal is a dog that has Canine Cognitive Dysfunction Syndrome (CCDS).

15. The method of claim 1 , wherein the composition is a pet food or pet treat and comprises from about 15 wt. % to about 50 wt. % crude protein, about 5 wt. % to about 40 wt. % fat, about 15 wt. % to about 60 wt. % carbohydrate, an ash content no greater than about 15 wt. %, and a moisture content from about 5 wt. % to about 20 wt. %.

16. The method of claim 1 , wherein the aging companion animal is a canine, and the composition has a protein content of about 20 wt. % to about 30 wt. %.

17. The method of claim 1 , wherein the aging companion animal is a feline, and the composition has a protein content of about 35 wt. % to about 45 wt. %.

18. The method of claim 1 , wherein the aging companion animal is geriatric.

19. The method of claim 1 , wherein the composition comprises from 0.1 to 40 times the recommended daily requirement of B vitamins.

20. The method of claim 1 , wherein the composition comprises about 0.0001% to about 25% of antioxidants.

21. A method comprising:

identifying an aging canine or aging feline in which enhancement of cognitive function is desired; and

administering a composition to the aging canine or aging feline in which enhancement of cognitive function is desired, the composition is administered on a daily basis and comprises effective amounts of arginine and docosahexaenoic acid (DHA), wherein the DHA is about 0.1% to about 50% of the composition, and the administering of the composition on a daily basis for a time period results in enhanced cognitive function in the aging canine or aging feline compared with an equivalent aging canine or aging feline not administered the composition for an equivalent time period.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2023
From: PAN, YUANLONG
To: NESTEC S.A.
Reel/Frame 065762/0736 →
MERGER Recorded Dec 5, 2023
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 065774/0733 →
Continuity (6)
Continuation 16150979 · Oct 3, 2018
Continuation 15440702 · Feb 23, 2017
Continuation In Part 12734013
Provisional Application 61137382 · Jul 30, 2008
Provisional Application 61010097 · Jan 4, 2008
Related Publication 20210205373A1 · Jul 8, 2021